<DOC>
	<DOC>NCT00168922</DOC>
	<brief_summary>Determination of response rate Assessment of toxicity and determination of "time to progression"</brief_summary>
	<brief_title>Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)</brief_title>
	<detailed_description>Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients with histological proven, curative non treatable small lung cell carcinoma Recurrence &gt;8 weeks, &gt; 1 year after 1st line treatment with platin and etoposide polychemotherapy, without brain metastases Brain metastases WHOPS 3 4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>recurrent SCLC</keyword>
</DOC>